- Home
- MIRM vs DAVE Comparison
MIRM vs DAVE Comparison
Compare MIRM & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- DAVE
- Stock Information
- Founded
- MIRM 2018
- DAVE 2017
- Country
- MIRM United States
- DAVE United States
- Employees
- MIRM N/A
- DAVE N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- DAVE Retail: Computer Software & Peripheral Equipment
- Sector
- MIRM Health Care
- DAVE Technology
- Exchange
- MIRM Nasdaq
- DAVE Nasdaq
- Market Cap
- MIRM 3.3B
- DAVE 3.2B
- IPO Year
- MIRM 2019
- DAVE N/A
- Fundamental
- Price
- MIRM $76.06
- DAVE $194.65
- Analyst Decision
- MIRM Strong Buy
- DAVE Strong Buy
- Analyst Count
- MIRM 9
- DAVE 6
- Target Price
- MIRM $73.89
- DAVE $262.17
- AVG Volume (30 Days)
- MIRM 914.8K
- DAVE 458.9K
- Earning Date
- MIRM 08-06-2025
- DAVE 08-06-2025
- Dividend Yield
- MIRM N/A
- DAVE N/A
- EPS Growth
- MIRM N/A
- DAVE 70.95
- EPS
- MIRM N/A
- DAVE 3.84
- Revenue
- MIRM $429,161,000.00
- DAVE $433,065,000.00
- Revenue This Year
- MIRM $52.71
- DAVE $48.07
- Revenue Next Year
- MIRM $19.71
- DAVE $15.28
- P/E Ratio
- MIRM N/A
- DAVE $51.00
- Revenue Growth
- MIRM 62.33
- DAVE 47.97
- 52 Week Low
- MIRM $36.86
- DAVE $31.75
- 52 Week High
- MIRM $76.40
- DAVE $286.45
- Technical
- Relative Strength Index (RSI)
- MIRM 77.75
- DAVE 44.01
- Support Level
- MIRM $73.12
- DAVE $198.63
- Resistance Level
- MIRM $76.02
- DAVE $217.60
- Average True Range (ATR)
- MIRM 2.39
- DAVE 12.25
- MACD
- MIRM 0.04
- DAVE 0.45
- Stochastic Oscillator
- MIRM 96.66
- DAVE 32.02
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.